Narihiro Satoshi, Suwa Katsuhito, Ushigome Takuro, Ohtsu Masamichi, Ryu Syunjin, Shimoyama Yuya, Okamoto Tomoyoshi, Yanaga Katsuhiko
Department of Surgery, The Jikei University Daisan Hospital, Tokyo, Japan
Department of Surgery, The Jikei University Daisan Hospital, Tokyo, Japan.
In Vivo. 2018 Nov-Dec;32(6):1643-1646. doi: 10.21873/invivo.11426.
To retrospectively examine efficacy and safety of oral combination of trifluridine and tipiracil hydrochloride (TAS-102) as the second-line therapeutic agent for unresectable colorectal cancer.
Treatment outcomes of 17 patients who had received TAS-102 at our Institution from January 2015 to January 2017 were analyzed. The indications for second-line TAS-102 treatment were intolerance to other multi-drug combination (four patients) or patient refusal of the standard second-line therapy (13 patients).
Among 17 patients who received TAS-102 as second-line therapy, partial response was observed in two (12%) and stable disease in two (12%). Outcomes of TAS-102 given as second-line therapy were: median overall survival of 5 months, response rate of 12% and disease control of 24%. Overall, no adverse events other than neutropenia were noted.
Our findings suggest a beneficial role of TAS-102 in second-line therapy for unresectable colorectal carcinoma.
回顾性研究口服曲氟尿苷和盐酸替匹嘧啶联合用药（TAS-102）作为不可切除结直肠癌二线治疗药物的疗效和安全性。
分析了2015年1月至2017年1月在我院接受TAS-102治疗的17例患者的治疗结果。二线TAS-102治疗的指征为对其他多药联合治疗不耐受（4例）或患者拒绝标准二线治疗（13例）。
在接受TAS-102作为二线治疗的17例患者中，观察到2例（12%）部分缓解，2例（12%）疾病稳定。TAS-102作为二线治疗的结果为：中位总生存期5个月，缓解率12%，疾病控制率24%。总体而言，除中性粒细胞减少外未观察到其他不良事件。
我们的研究结果表明TAS-102在不可切除结直肠癌的二线治疗中具有有益作用。
